Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 4Gastrointestinal 4Head & Neck 2Thoracic 1Sarcoma 1Breast 1

Conditions

Tobacco Use Disorder 1Precancerous Conditions 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 335Pemetrexed 276Cisplatin 228Paclitaxel 193pembrolizumab 178Erlotinib Hydrochloride 173Docetaxel 154Gemcitabine 126Nivolumab 112Bevacizumab 112Radiotherapy 84Etoposide 68durvalumab 62atezolizumab 59Ipilimumab 51Radiosurgery 49osimertinib 42130-nm albumin-bound paclitaxel 40Afatinib 39Gefitinib 38Cetuximab 38Albumin-Bound Paclitaxel 37Taxes 32Vinorelbine 29Radiation 29Topotecan 28Drug Therapy 25Crizotinib 23Platinum 21Dexamethasone 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sulindac × Thoracic × Clear all
NCT00368927 2014-05-23

Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

National Cancer Institute (NCI)

Phase 2 Completed
61 enrolled 11 charts
Other neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Precancerous Conditions, Tobacco Use Disorder

Data powered by HemOnc (CC BY 4.0) Colophon âš¡